A5083156311- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Digestive system and related health
- Nutritional Studies and Diet
- Obesity, Physical Activity, Diet
- Physical Activity and Health
- Advances in Oncology and Radiotherapy
- BRCA gene mutations in cancer
- Organ Transplantation Techniques and Outcomes
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Esophageal and GI Pathology
- Healthcare Policy and Management
- Appendicitis Diagnosis and Management
- Molecular Biology Techniques and Applications
- Nutrition, Genetics, and Disease
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Sarcoma Diagnosis and Treatment
- Diagnosis and Treatment of Venous Diseases
- Radiomics and Machine Learning in Medical Imaging
Montefiore Medical Center
2019-2024
Albert Einstein College of Medicine
2020-2024
Stanford University
2008-2015
University Hospital and Clinics
2013
Abstract There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome challenge by providing insight into sarcomas’ molecular drivers. Through targeted panel sequencing 7494 sarcomas representing 44 histologies, we identify highly recurrent type-specific alterations that aid in diagnosis treatment decisions. Sequencing lead to refinement or reassignment...
Abstract Black people have a higher incidence of colorectal cancer and worse survival rates when compared with white people. Comprehensive genomic profiling was performed in 46,140 adenocarcinoma cases. Ancestry-informative markers identified 5,301 patients African descent (AFR) 33,770 European (EUR). AFR were younger, had fewer microsatellite instability–high (MSI-H) tumors, significantly more frequent alterations KRAS, APC, PIK3CA. increased frequency KRAS mutations, specifically KRASG12D...
Importance The KEYNOTE-177 trial demonstrated that patients with metastatic colorectal cancer (MCRC) high microsatellite instability (MSI-H) and/or mismatch repair deficiency (DMMR) have better outcomes when receiving first-line immune checkpoint inhibitors (ICIs) compared chemotherapy. Data on performance of ICIs in MCRC standard practice settings remain limited, and direct MMR vs MSI outcome association comparisons are lacking. Objective To validate (determined by next-generation...
Gastrointestinal (GI) emergencies may cause substantial morbidity. Our aims were to characterize the national clinical and economic burden of GI visits emergency departments (EDs) in United States.We performed an observational cross-sectional study using 2007 Nationwide Emergency Department Sample, largest US all-payer ED database, identify leading causes for due diseases their associated charges, stratified by age sex. Logistic regression was used analyze predictors hospitalization after...
OBJECTIVES: Heritable and environmental factors may contribute to differences in colorectal cancer (CRC) incidence across populations. We capitalized on the resources of California Cancer Registry (CCR) California's diverse Asian population perform a cohort study exploring relationships between CRC incidence, nativity, neighborhood-level subgroups. METHODS: identified cases CCR from 1990 2004 calculated age-adjusted rates for non-Hispanic Whites US-born vs. foreign-born ethnic subgroups,...
Abstract Purpose The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel belinostat prodrug, copper-bis-belinostat (Cubisbel), vitro and ex vivo , designed overcome the pharmacokinetic challenges of belinostat. Methods metabolism each HDACi was human liver microsomes (HLMs) using mass spectrometry. Next, effect Cubisbel on cell growth, HDAC activity,...
Individuals of African (AFR) ancestry have a higher incidence colorectal cancer (CRC) than those European (EUR) and exhibit significant health disparities. Previous studies noted differences in the tumor microenvironment between AFR EUR patients with CRC. However, molecular regulatory processes that underpin these immune remain largely unknown.
46 Background: The KEYNOTE-177 randomized controlled trial demonstrated that mCRC patients with MSI high (MSI-H) and/or deficient MMR (dMMR) have better outcomes on first-line ICI than chemotherapy. This study aimed to evaluate by next-generation sequencing (NGS) as a predictive biomarker of effectiveness in real-world settings, and compare (NGS), dMMR (immunohistochemistry, IHC), TMB (10 mut/Mb cutoff) predicting outcomes. Methods: A prospectively declared statistical analysis plan compared...
374 Background: Screening of persons with newly diagnosed colorectal cancer (CRC) for Lynch Syndrome (LS) can yield substantial population-level benefits at acceptable costs, presuming sufficient uptake genetic testing by first-degree relatives (FDRs) LS probands. We reviewed systematically the published literature addressing frequency and predictors FDRs Methods: A search was conducted in four electronic databases (CINAHL, PsycInfo, PUBMED, SCOPUS) articles through May 2011 that reported...
164 Background: Blood-based ECD has the potential to reduce mortality rates by improving strategies for, adoption of, and adherence screening. A deeper understanding of cancer genomic landscape across genetic ancestries will aid comparable detection performance a broad population. We evaluated mutational in patients with CRC ancestries. Methods: 16,080 de-identified stage I-IV who had personalized, tumor-informed commercial ctDNA testing (Signatera) based on whole exome sequencing (WES) were...
•One-third of RAS/BRAF WT mCRC has EGFR mAb primary resistance gene alterations.•ERBB2, RTK, and RAS/PI3K pathway alterations were associated with resistance.•RAS/BRAF/EGFR mutations KRAS/MET amplification are more prevalent post-EGFR treatment.•Acquired RTK time exposure.•Comprehensive genomic profiling detects a broad set in mCRC. BackgroundPatients metastatic colorectal cancer (mCRC) RAS- or BRAF-mutant tumors do not benefit from epidermal growth factor receptor (EGFR) monoclonal antibody...
e15527 Background: Blood-based ECD has the potential to reduce mortality rates by improving strategies for adoption of and adherence screening. As health disparities in incidence CRC across minority populations are known exist, we evaluated genomic landscape patients with genetic ancestries. Methods: De-identified (N = 16,337) stage I-IV had personalized, tumor-informed commercial ctDNA testing (Signatera TM ) based on whole exome sequencing. Genetic ancestry determined via supervised local...